John W. LaRocca - 16 Sep 2025 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
18 Sep 2025, 21:01:12 UTC
Prior SEC filing
22 Jan 2025
Next SEC filing
06 Nov 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ John LaRocca
Filing notes and source

Key filing fact

John W. LaRocca filed Form 4 for Y-mAbs Therapeutics, Inc. (YMAB) on 18 Sep 2025.

Key facts

  • This page summarizes John W. LaRocca's Form 4 filing for Y-mAbs Therapeutics, Inc. (YMAB).
  • 3 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 18 Sep 2025, 21:01.

Change

  • Previous filing in this sequence was filed on 22 Jan 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001732197 Primary reporting owner

LaRocca John

Relationship
SVP, General Counsel & Secry
Address
C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, NEW YORK
Signature
/s/ John LaRocca
Signature date
18 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

YMAB transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-21,500
Change %
-100%
Price
Shares after
0
Date
16 Sep 2025
Ownership
Direct
Footnotes
F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

YMAB transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-142,600
Change %
-100%
Price
Shares after
0
Date
16 Sep 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
142,600
Exercise price
$9.83
Footnotes
F1, F4
YMAB transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares
-42,900
Change %
-100%
Price
Shares after
0
Date
16 Sep 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
42,900
Exercise price
$6.16
Footnotes
F1, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

John W. LaRocca is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 4, 2025, by and among Y-mAbs Therapeutics, Inc. (the "Issuer"), Yosemite Merger Sub, Inc. ("Purchaser"), Perseus BidCo US, Inc., a Delaware corporation ("Parent"), and Stark International Lux, a Luxembourg private limited liability company ("Ultimate Parent"), on September 16, 2025, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").

Footnote F2

Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock on the vesting dates of the RSU.

Footnote F3

At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the "Effective Time"), pursuant to the Merger Agreement, each RSU award outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (a) the total number of Shares issuable in settlement of such RSU award immediately prior to the Effective Time, multiplied by (b) the right to receive $8.60 per Share, in cash, without interest, subject to any applicable withholding of taxes (the "Merger Consideration").

Footnote F4

At the Effective Time, pursuant to the Merger Agreement, each stock option ("Option") outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, equal to the product of (a) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess of the Merger Consideration over the exercise price payable per Share under such Option. Any Options with an exercise price equal to or in excess of the Merger Consideration were cancelled for no consideration.

SEC remarks

The foregoing descriptions in the footnotes to this Form 4 are qualified in their entirety by reference to the terms of the Merger Agreement. In the event of any conflict between the descriptions above and the terms set forth in the Merger Agreement, the terms set forth in the Merger Agreement shall control.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .